Michael Heung is a Nephrology physician affiliated with University of Michigan. OpenAlex indexes 210 publications with 13,077 citations (h-index 42); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 21 Feb 2020.
Clinical trials
- Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring
Sponsor: University of Michigan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20251 payment
- Potrero Medical, Inc.Program year20221 payment
- Vifor Pharma, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
56.9%Angiotensin receptor blocker (ARB)19.7%Losartan Potassium100%Part D≥27 patientsCalcium channel blocker13.7%Amlodipine Besylate66%Nifedipine Er35%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
33.7%SGLT2 inhibitor14%Farxiga71%Jardiance29%Part D<11 patientsCorticosteroid9%Prednisone100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
6.2%Xanthine oxidase inhibitor6.2%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- In-Hospital and 1-Year Mortality Trends in a National Cohort of US Veterans with Acute Kidney Injury
Clinical Journal of the American Society of Nephrology
2022 - Generalizability of an acute kidney injury prediction model across health systems
Nature Machine Intelligence
2022 - Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019
JAMA Network Open
2021 - Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
Intensive Care Medicine
2020 - CKD Awareness Among US Adults by Future Risk of Kidney Failure
American Journal of Kidney Diseases
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”